Tenax Therapeutics Inc (TENX)

[casenumber]

“MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the pricing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax.

The offering is comprised of 5,181,346 units, priced at an offering price of $1.93 per unit, with each unit consisting of one share of Series A convertible preferred stock, having a conversion price of $1.93, a two-year warrant to purchase one share of common stock with an exercise price of $1.93 per share, and a five-year warrant to purchase one share of common stock with an exercise price of $1.93 per share. “